Changes in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening

Authors:

Abstract
The effects of recent conflicting guidance on prostate-specific antigen (PSA) screening for prostate cancer during the past decade are not yet fully understood. In 2012, the US Preventive Services Task Force (USPSTF) issued a grade D recommendation against PSA-based screening for prostate cancer.1,2 At the time, the guideline expressed moderate to high certainty that the harms of PSA screening outweighed the benefits.3,4 In the subsequent period, the guideline was rapidly incorporated into practice, and there have been measurable decreases in rates of PSA testing and diagnostic biopsies, as well as the number of prostate cancers identified in the United States.5-7 There are also increasing concerns that reductions in PSA testing associated with the USPSTF statement were temporally associated with increases in the incidence of prostate cancers diagnosed at an advanced or metastatic stage.8,9

This publication has 37 references indexed in Scilit: